Lyell Immunopharma acquires exclusive global rights to LYL273

Lyell Immunopharma (LYEL) announced it has strengthened its solid tumor pipeline by acquiring global rights to LYL273, a novel autologous guanylyl cyclase-C-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer and other GCC-expressing cancers, from Innovative Cellular Therapeutics. Patients with refractory mCRC treated with LYL273 in a Phase 1 clinical trial conducted in the United States achieved a 67% overall response rate and an 83% disease control rate per Response Evaluation Criteria in Solid Tumors 1.1 with a manageable safety profile at the highest dose level studied to date. LYL273 is a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration and cancer cell killing in the hostile solid tumor microenvironment.